Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. (hereinafter referred to as Tri-Prime) is a leading biopharmaceutical enterprise with a registered capital of RMB 110 million Yuan. It is specialized in research, development, production and sales of medical & biotechnological products, including genetic engineering drugs, genetic engineering vaccine and diagnostic reagent, and also carries out technology trade and technical consulting services related thereto.
Founded in 1992, Tri-Prime was co-founded by Dr. Hou Yunde, former vice president of the Chinese Academy of Engineering and Mr. Cheng Yongqing, who is one of China's first professional managers engaged in high-tech entrepreneurship and venture capital investment.
As the main product of Tri-Prime, Recombinant Human Interferon-α1b (Hapgen?) is China’s first genetic engineering Class Ⅰ new drug, with its own independent intellectual property rights. Used to treat various kinds of viral diseases and malignant tumors, Hapgen? has established its top notch brand position in China, and generated great economic and social benefits.
Tri-Prime has developed strong R&D capabilities and has undertaken a number of critical new drug development projects at the Beijing municipal level and state level. Since 2001, a post-doctoral research station has established in Tri-Prime and approved by the State Ministry of Personnel. Currently, Tri-Prime has more than 10 approved products with certificates for manufacturing and sales, and holds over 10 new candidate products in pre-clinical and clinical stage. In addition, Tri-Prime owns more than 40 invention patents from China, the US and other countries.